Palisade bio to present at the h.c. wainwright bioconnect virtual conference and biotech showcase

Carlsbad, calif., dec. 29, 2021 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, announces that they will present at the h.c. wainwright bioconnect virtual conference taking place january 10-13, 2022, and at biotech showcase taking place january 10-12, 2022. the palisade bio management team also will be hosting investor meetings during that period and talking about their lead program, lb1148. lb1148 has shown significant results in a phase 2 trial with a 1.1-day improvement in return to bowel function following gi surgery in the mean.
PALI Ratings Summary
PALI Quant Ranking